Literature DB >> 14720452

Hepatocellular carcinoma: updates in primary prevention.

Will J Fecht1, Alex S Befeler.   

Abstract

Hepatocellular carcinoma is a significant cause of mortality worldwide and a growing problem in the United States. Treatment options are often limited, and median survival is less than 1 year. Thus, prevention may provide the best opportunity to alter the natural history of this disease. Primary prevention is best exemplified by the successes of such public health measures as universal hepatitis B vaccination. Such antiviral therapies as interferon may also have a role. Lessons can be learned from complementary and alternative medicine. Nevertheless, more work is needed in understanding hepatocarcinogenesis and in developing models to assess potential chemopreventive agents.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14720452     DOI: 10.1007/s11894-004-0024-3

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  46 in total

1.  Molecular pathogenesis of human hepatocellular carcinoma.

Authors:  Snorri S Thorgeirsson; Joe W Grisham
Journal:  Nat Genet       Date:  2002-08       Impact factor: 38.330

2.  Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People's Republic of China.

Authors:  J S Wang; X Shen; X He; Y R Zhu; B C Zhang; J B Wang; G S Qian; S Y Kuang; A Zarba; P A Egner; L P Jacobson; A Muñoz; K J Helzlsouer; J D Groopman; T W Kensler
Journal:  J Natl Cancer Inst       Date:  1999-02-17       Impact factor: 13.506

3.  Hepatocellular carcinoma.

Authors:  A M Di Bisceglie; R L Carithers; G J Gores
Journal:  Hepatology       Date:  1998-10       Impact factor: 17.425

4.  The long term efficacy of glycyrrhizin in chronic hepatitis C patients.

Authors:  Y Arase; K Ikeda; N Murashima; K Chayama; A Tsubota; I Koida; Y Suzuki; S Saitoh; M Kobayashi; H Kumada
Journal:  Cancer       Date:  1997-04-15       Impact factor: 6.860

Review 5.  Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity.

Authors: 
Journal:  Lancet       Date:  2000-02-12       Impact factor: 79.321

6.  A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma.

Authors:  F Donato; P Boffetta; M Puoti
Journal:  Int J Cancer       Date:  1998-01-30       Impact factor: 7.396

Review 7.  Prevention of hepatocellular carcinoma in chronic liver disease: molecular markers and clinical implications.

Authors:  F N Plesch; S Kubicka; M P Manns
Journal:  Dig Dis       Date:  2001       Impact factor: 2.404

8.  Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis.

Authors:  C Niederau; R Fischer; A Sonnenberg; W Stremmel; H J Trampisch; G Strohmeyer
Journal:  N Engl J Med       Date:  1985-11-14       Impact factor: 91.245

9.  Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma.

Authors:  R K Ross; J M Yuan; M C Yu; G N Wogan; G S Qian; J T Tu; J D Groopman; Y T Gao; B E Henderson
Journal:  Lancet       Date:  1992-04-18       Impact factor: 79.321

10.  Cancer statistics, 2003.

Authors:  Ahmedin Jemal; Taylor Murray; Alicia Samuels; Asma Ghafoor; Elizabeth Ward; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2003 Jan-Feb       Impact factor: 508.702

View more
  2 in total

1.  Reactive oxygen species: role in the development of cancer and various chronic conditions.

Authors:  Gulam Waris; Haseeb Ahsan
Journal:  J Carcinog       Date:  2006-05-11

2.  Cytotoxic potential of few Indian fruit peels through 3-(4,5-dimethylthiazol-yl)-2,5-diphenyltetrazolium bromide assay on HepG2 cells.

Authors:  Munish Garg; Kusum Lata; Saurabh Satija
Journal:  Indian J Pharmacol       Date:  2016 Jan-Feb       Impact factor: 1.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.